Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.
about
Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialistThe Clinician's Toolbox: Assessing the Sexual Impacts of Cancer on Adolescents and Young Adults with Cancer (AYAC)Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complicationsA clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapyUltra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.The effect of vitamin D on vaginal atrophy in postmenopausal womenExemestane in the adjuvant treatment of breast cancer in postmenopausal women.Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.Evaluating Sexual Nursing Care Intervention for Reducing Sexual Dysfunction in Indonesian Cervical Cancer SurvivorsBreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.Non-ovarian aromatization is required to activate female sexual motivation in testosterone-treated ovariectomized quailA review of the use of exemestane in early breast cancer.Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.The expanding use of third-generation aromatase inhibitors: what the general internist needs to knowOn the role of brain aromatase in females: why are estrogens produced locally when they are available systemically?Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.Endocrine therapy for breast cancer in the primary care setting
P2860
Q26771021-FBCDBD8E-BDDD-4E5A-AB2F-6358E3F72C78Q26782823-749354CE-F6C9-4D6B-9F98-188B2C85798BQ28079287-C88DF9B7-340E-4535-B4B6-13BB6FD8E412Q28383280-BC9E4C6A-BCC5-4155-8A11-94A68ED7430BQ33605919-B855C62F-1E13-4B07-964A-F7380ACD1686Q33628455-79168D33-A10D-4677-8B65-816EF7681154Q35292893-54E5EF9F-2A9E-4271-B19E-1B9D2D34DCACQ35440357-68D933CF-BE75-4D77-8937-E8C906CFC7B7Q35634204-0A93DCC9-8958-4A5B-8A9C-60B330FC93B7Q36226279-5CD5AA65-1979-4999-BD7A-7DCCCB0BF87EQ36283422-270D5379-485D-490C-B4A1-87A1B8993AF6Q37026519-0A689D3F-E00C-45F1-98AE-CD31ADCDC471Q37230265-F8F42902-4DBD-4352-B523-B57C0228DA1FQ37292414-FD764933-E364-4C96-95F2-8B3EAD619252Q37390076-40296854-52A5-4851-8130-50E927CD35E8Q47585459-4730F4AB-A93F-4F9D-8CF5-6A6523178500Q47722034-7ABDD928-15DA-4998-933A-0AA80BC5EE0BQ57108564-3F1FB91E-F951-432F-A00A-B1245CB465A4
P2860
Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Management of sexual dysfuncti ...... t aromatase inhibitor therapy.
@ast
Management of sexual dysfuncti ...... t aromatase inhibitor therapy.
@en
type
label
Management of sexual dysfuncti ...... t aromatase inhibitor therapy.
@ast
Management of sexual dysfuncti ...... t aromatase inhibitor therapy.
@en
prefLabel
Management of sexual dysfuncti ...... t aromatase inhibitor therapy.
@ast
Management of sexual dysfuncti ...... t aromatase inhibitor therapy.
@en
P2093
P2860
P356
P1433
P1476
Management of sexual dysfuncti ...... nt aromatase inhibitor therapy
@en
P2093
P2860
P304
P356
10.3747/CO.2007.151
P478
14 Suppl 1
P577
2007-12-01T00:00:00Z